Showing 5401-5410 of 7168 results for "".
- Highlights from Maui Derm 2024https://practicaldermatology.com/news/highlights-from-maui-derm-2024/2462227/The Maui Derm 2024 Conference showcased a wide array of advancements in dermatology, from innovative treatments to exciting new therapies, to business opportunities to the latest research. Here, Practical Dermatology recap
- ARCADIA 1 and 2: Nemolizumab Reduces Itch, Sleep Disturbance in Atopic Dermatitishttps://practicaldermatology.com/news/arcadia-nemolizumab-reduces-itch-sleep-disturbance-in-atopic-dermatitis/2462226/Nemolizumab, an interleukin-31 (IL-31) receptor alpha antagonist, demonstrated significant efficacy in adults and adolescents with atopic dermatitis (AD) in a pair of identical trials, according to new study results pre
- Deucravacitinib Shows Sustained Response, Safety Profile: Analyseshttps://practicaldermatology.com/news/deucravacitinib-shows-sustained-response-safety-profile-analyses/2462221/Deucravacitinib (SOTYKTU, Bristol Myers Squibb) is a first-in-class, oral, selective allosteric TYK2 inhibitor, and has been approved in the United States, European Union, and other countries for use in adults with mode
- Upadacitinib Improves Night-time Itch and Sleep Disturbance: Studyhttps://practicaldermatology.com/news/analysis-upadacitinib-improves-night-time-itch-and-sleep-disturbance/2462217/Researchers publishing the poster at Maui Derm 2024 analyzed integrated data from the Measure Up 1 and Measure Up 2 phase-3 randomized, double-blinded studies looking the safety and efficacy of upadacitinib 15 mg (UPA 1
- Analysis: Women, Minorities Underrepresented in Psoriasis Researchhttps://practicaldermatology.com/news/analysis-women-minorities-underrepresented-in-psoriasis-research/2462215/A new analysis suggested that women and minorities are consistently underrepresented in the psoriasis and hidradenitis suppurativa (HS) medical literature. "Ensuring clinical trial populations reflect the racial, ethnic, and sex makeup of patient populations is important for
- Researchers Identify Factors Limiting New Treatment Decisions for HShttps://practicaldermatology.com/news/factors-affecting-treatment-selection-among-patients-with-hidradenitis-suppurativa/2462211/Researchers seeking to address the gap between evidence-based guidelines and clinical practice in the treatment of hidradenitis suppurativa (HS) have identified several factors influencing patient decision-making. The open-ended, two-center study, conducted through open-ended interviews
- Skin Deep Solutions: Navigating Acne and Rosacea with Quality Skin Carehttps://practicaldermatology.com/news/skin-deep-solutions-navigating-acne-and-rosacea-with-quality-skin-care/2462209/In the ever-evolving landscape of dermatology, Hilary Baldwin, MD, a board-certified dermatologist, and the medical director of the Acne Treatment & Research Center in Brooklyn, recently shed light on the critical role
- Novartis Set to Acquire Calypso Biotech, Focused on IL-15 Targeted Therapieshttps://practicaldermatology.com/news/novartis-set-to-acquire-calypso-biotech-focused-on-il-15-targeted-therapies/2462204/European-based biotech manufacturer Calypso has entered into an agreement to be acquired by Novartis, according to a press release. "We are excited for this transaction with Novartis," Calypso CEO and Founder Alain Vicari said in a news release. "As part of the
- Co-occurring Autistic Spectrum Disorder Mediates ADHD on Atopic Dermatitis, Acnehttps://practicaldermatology.com/news/co-occurring-asd-mediates-impact-of-adhd-on-atopic-dermatitis-and-acne-a-retrospective-cohort-study/2462200/Both male and females who were diagnosed with attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) showed different risks for acne and eczema, according to a study. "Our study is the first to examine the association between ASD, ADHD, and two of the most commo
- Triple Combo Acne Gel Well-tolerated in Two Studieshttps://practicaldermatology.com/news/triple-combo-acne-gel-well-tolerated-in-phase-2-study/2462194/A triple combination acne gel (IDP-126) was shown to be safe and effective in two phase 3 studies, according to a new analysis. Researchers publishing